Henlius Reports Near 10% Revenue Growth In First Half Of 2024
The Company Reported Increased Revenue Boosted By Increased Sales
Henlius’ results for the first half of 2024 have shown a continued trend in growing sales of its core biological products on the backdrop of the company’s ongoing privatization by parent company Fosun Pharmaceutical.
